Press release
Opioid-Induced Respiratory Depression (OIRD) Market Set to Witness Significant Growth by 2025-2034
Opioid-Induced Respiratory Depression (OIRD) Market
Opioid-Induced Respiratory Depression (OIRD) is one of the most severe and life-threatening side effects associated with opioid use, both in medical and non-medical contexts. Characterized by dangerously slowed or halted breathing, OIRD is a leading cause of opioid-related mortality worldwide. As the use of opioids in pain management continues and illicit opioid misuse rises, the global demand for effective prevention and reversal agents is accelerating.
The market is seeing significant momentum with the growing adoption of naloxone formulations, long-acting opioid antagonists, and next-generation rescue therapies. Coupled with supportive government programs and rising public health awareness, the OIRD market, valued at USD $1.2 billion in 2024, is expected to reach USD $2.8 billion by 2034, expanding at a CAGR of 8.5% during the forecast period.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/70807
Market Overview
• Market Size (2024): USD $1.2 billion
• Forecasted Market Size (2034): USD $2.8 billion
• CAGR (2024-2034): XX%
• Key Drivers: Rising opioid prescriptions and misuse, growing overdose-related deaths, and government-supported harm reduction programs.
• Key Challenges: High relapse rates, unequal global access to reversal therapies, and regulatory hurdles in some countries.
• Leading Players: Emergent BioSolutions, Indivior, Pfizer, Opiant Pharmaceuticals, Teva Pharmaceuticals, among others.
The market is moderately consolidated, with naloxone-based products dominating, but new therapies are emerging to provide longer-lasting and more patient-friendly options.
Segmentation Analysis
By Treatment Type
• Opioid Antagonists
o Naloxone (injectable and nasal spray)
o Naltrexone (oral and extended-release)
• Long-Acting Rescue Agents (pipeline therapies)
• Supportive Respiratory Care
By Patient Group
• Chronic Pain Patients on Opioids
• Cancer Pain Management Patients
• Post-Surgical Patients
• Illicit Opioid Users
By End Use
• Hospitals & Emergency Care Units
• Ambulatory Surgical Centers
• Community & Homecare Settings
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Community Distribution Programs
Segmentation Summary:
Naloxone remains the gold standard for OIRD reversal, especially in community and emergency settings. However, pipeline long-acting agents and combination therapies are expected to redefine the market landscape by 2034.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/70807/opioid-induced-respiratory-depression-market
Regional Analysis
North America
• Largest market due to high opioid prescription rates and overdose cases in the U.S. and Canada.
• Strong government funding and OTC availability of naloxone are boosting adoption.
Europe
• Significant market presence, particularly in Western Europe with strong harm-reduction frameworks.
• Increasing use of naloxone in both hospital and community settings.
Asia-Pacific (APAC)
• Fastest-growing region, fueled by increasing opioid misuse in countries like India and rising post-surgical opioid prescriptions in Japan and China.
• Expanding healthcare infrastructure supports growth.
Middle East & Africa (MEA)
• Emerging opportunities as governments address rising opioid misuse.
• Limited access to advanced formulations in rural areas.
Latin America
• Brazil and Mexico showing increasing demand due to rising opioid misuse.
• Government and NGO-backed naloxone distribution programs expanding reach.
Regional Summary:
North America dominates revenue share, but Asia-Pacific is projected to grow at the fastest CAGR, supported by growing demand for surgical pain management solutions and addiction treatments.
Market Dynamics
Key Growth Drivers
• Rising opioid epidemic and overdose-related mortality.
• Expanding government-backed naloxone distribution programs.
• Increasing use of opioids in post-surgical and cancer pain management.
• Pipeline development of long-acting and user-friendly rescue agents.
Key Challenges
• Relapse risks and repeated OIRD episodes post-reversal.
• Unequal access in low-income countries.
• Regulatory restrictions on OTC naloxone in some regions.
• Limited awareness in rural populations.
Latest Trends
• OTC approvals for naloxone nasal sprays in the U.S. and Europe.
• Clinical trials for novel antagonists with extended action.
• Integration of digital monitoring tools for at-risk patients.
• Partnerships between pharma companies and governments for mass distribution programs.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70807
Competitor Analysis
Major Players in the OIRD Market:
1. Emergent BioSolutions, Inc. (Narcan Nasal Spray)
2. Indivior PLC
3. Opiant Pharmaceuticals, Inc. (Indivior)
4. Pfizer Inc.
5. Teva Pharmaceutical Industries Ltd.
6. Hikma Pharmaceuticals PLC
7. Alkermes plc
8. Amphastar Pharmaceuticals, Inc.
9. Dr. Reddy's Laboratories
10. Glenmark Pharmaceuticals
11. Sandoz (Novartis)
12. Mallinckrodt Pharmaceuticals
13. Apotex Inc.
14. Camurus AB
15. Braeburn Inc.
Competitive Summary:
Emergent BioSolutions leads with Narcan, while Opiant (Indivior) and Teva compete with multiple naloxone formulations. Companies like Camurus and Braeburn are exploring long-acting injectable antagonists to reduce the need for repeat dosing. Partnerships with NGOs and governments are central to expanding global access.
Conclusion
The Opioid-Induced Respiratory Depression (OIRD) Market is expected to expand significantly by 2034, driven by the escalating opioid crisis and growing emphasis on overdose prevention. While naloxone remains the cornerstone, innovation in long-acting formulations and digital monitoring integration will shape the future landscape.
This report is also available in the following languages : Japanese (オピオイド誘発性呼吸抑制市場), Korean (오피오이드 유발 호흡 억제 시장), Chinese (阿片类药物引起的呼吸抑制市场), French (Marché de la dépression respiratoire induite par les opioïdes), German (Markt für opioidinduzierte Atemdepression), and Italian (Mercato della depressione respiratoria indotta da oppioidi), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/70807
Our More Reports:
Atypical Hemolytic Uremic Syndrome Market
https://exactitudeconsultancy.com/reports/71273/atypical-hemolytic-uremic-syndrome-market
Beta Thalassemia Market
https://exactitudeconsultancy.com/reports/71274/beta-thalassemia-market
Chronic Venous Insufficiency Market
https://exactitudeconsultancy.com/reports/71275/chronic-venous-insufficiency-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Opioid-Induced Respiratory Depression (OIRD) Market Set to Witness Significant Growth by 2025-2034 here
News-ID: 4148107 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for OIRD
Opioid-Induced Respiratory Depression Market Industry Analysis by Size, Share, G …
Introduction
The Opioid-Induced Respiratory Depression (OIRD) Market is expanding as opioid prescription rates remain high and awareness grows about the risks of respiratory suppression linked to these medications. OIRD, a potentially fatal side effect of opioid use, can occur in post-operative pain management, chronic pain therapy, and illicit opioid abuse. Increasing adoption of advanced respiratory monitoring systems, wider access to reversal agents like naloxone, and innovations in opioid formulations with reduced…
Opioid Dependence Pipeline Insight 2025: Innovating Beyond Maintenance Therapy T …
Opioid dependence remains a persistent public health crisis, contributing to high rates of overdose, relapse, and mortality worldwide. While current treatment strategies-such as opioid agonist therapies and behavioral interventions-have improved patient outcomes, there is a critical need for more effective, long-lasting, and relapse-resistant therapies that target the neurobiological basis of addiction.
DelveInsight's "Opioid Dependence - Pipeline Insight, 2025" explores a dynamic pipeline of 25+ emerging therapies aimed at transforming the treatment…
Capnography Equipment Market to Reach USD 536.35 Million by 2032 at a 4.4% of CA …
The global capnography equipment market is poised for steady growth, with its valuation expected to increase from USD334 million in 2021 to USD536.35 million by 2032. This reflects a compound annual growth rate (CAGR) of 4.4% over the forecast period. The growing prevalence of respiratory disorders, coupled with the rising need for continuous respiratory monitoring, is driving the demand for capnography equipment in healthcare settings worldwide.
Capnography, a non-invasive method for…
Capnography Devices Market is Booming Worldwide | Dragerwerk AG & Co. KGaA., We …
Capnography is the process of extensive measurement and display of concentrations or partial pressures of carbon dioxide (CO2) in the respiratory gases by using a capnograph. It accurately measure the levels of carbon dioxide released into the bloodstream. The readings are presented as a graph of expiratory CO2 plotted against time or expired volume called as capnogram. A capnogram is direct monitoring of inhaled and exhaled concentrations of CO2…
Capnography Devices Market - Global Industry Insights,2025
Capnography is the process of extensive measurement and display of concentrations or partial pressures of carbon dioxide (CO2) in the respiratory gases by using a capnograph. It accurately measure the levels of carbon dioxide released into the bloodstream. The readings are presented as a graph of expiratory CO2 plotted against time or expired volume called as capnogram. A capnogram is direct monitoring of inhaled and exhaled concentrations of CO2…
Capnography Devices Market - Global Industry Insights, Trends, Size, Share, Outl …
Capnography is the process of extensive measurement and display of concentrations or partial pressures of carbon dioxide (CO2) in the respiratory gases by using a capnograph. It accurately measure the levels of carbon dioxide released into the bloodstream. The readings are presented as a graph of expiratory CO2 plotted against time or expired volume called as capnogram. A capnogram is direct monitoring of inhaled and exhaled concentrations of CO2…
